Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer | Future Oncology
Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study | Anticancer Research
Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study - Takai - 2021 -
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
These highlights do not include all the information needed to use JEVTANA safely and effectively. See full prescribing information for JEVTANA. JEVTANA® (cabazitaxel) injection, for intravenous use Initial U.S. Approval: 2010
a) Progression free survival (PFS) on cabazitaxel (CAB) as 2 nd or... | Download Scientific Diagram
Cabazitaxel for the treatment of castration-resistant prostate cancer | Future Oncology
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Lu-177 Vipivotide Tetraxetan Yields Similar OS Versus Cabazitaxel in mCRPC Progressing After Docetaxel
ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen | PLOS ONE
Kaplan–Meier curves of overall survival by treatment group (TROPIC... | Download Scientific Diagram
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer - ScienceDirect
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - ScienceDirect
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer | SpringerLink
Choosing Chemotherapy for Castration-Resistant Prostate Cancer
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer | NEJM
Journal of Clinical Oncology on X: "Cabazitaxel vs docetaxel as 1st line tx for metastatic castration-resistant prostate cancer (FIRSTANA trial) https://t.co/0DliBtSjsc #pcsm https://t.co/ZEHKYfmO8L" / X
The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients | BMC Cancer | Full Text
ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer - Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier ...
Overall survival (OS) after cabazitaxel treatment. a OS in the... | Download Scientific Diagram
